We are live on ! Find out more
SVA

Sinovac Biotech

Delisted

SVA was delisted on the 22nd of February, 2019.

35 hedge funds and large institutions have $77.3M invested in Sinovac Biotech in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,167% more call options, than puts

Call options by funds: $128K | Put options by funds: $3K

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

1.19% less ownership

Funds ownership: 26.31% → 25.13% (-1.2%)

13% less funds holding

Funds holding: 40 → 35 (-5)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

41% less capital inflows, than outflows

Capital inflows: $4.39M | Capital outflows: $7.48M

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
11
Reduced
11
Closed
13
Calls
$128​K
Puts
$3​K
Net Calls
+$125​K
Net Calls Change
+$126​K

SVA Hedge Fund Activity: Q1 2016 in Review

35 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech (SVA) for Q1 2016, worth a combined $77.3M — up 6.7% from $72.5M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of SVA and 8 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 11 added.

The largest buyer was Citigroup, opening a new position worth an estimated $1.7M. The largest seller was Fidelity International, exiting entirely with an estimated $6.24M sold.

  • 35 institutional investors held Sinovac Biotech (SVA) as of Q1 2016, down from 40 in Q4 2015.
  • Funds reported $77.3M of Sinovac Biotech stock for Q1 2016, up 6.7% quarter-over-quarter.
  • 8 funds opened new Sinovac Biotech positions in Q1 2016 and 13 closed out, a net change of -5 holders.
  • The largest Sinovac Biotech buyer in Q1 2016 was Citigroup, an estimated $1.7M added.
  • The largest Sinovac Biotech seller in Q1 2016 was Fidelity International, an estimated $6.24M sold.

Based on aggregated 13F filings for Q1 2016.